Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Keratosis, Actinic 1

Interventions

Carboplatin 127pembrolizumab 123Cisplatin 112Paclitaxel 102Gemcitabine 83Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 69Dexamethasone 59Cyclophosphamide 59Pemetrexed 54Bevacizumab 54Doxorubicin 52durvalumab 51Radiotherapy 49Capecitabine 48Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 39Etoposide 38atezolizumab 35Nivolumab 35Letrozole 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × BF-200 ALA × 90 days × Clear all
NCT05662202 2026-05-22

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Biofrontera Inc.

Phase 3 Active not recruiting
172 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡